Antifibrotic Preventive Effect of Polyethylene Glycol (PEG) 3350 in Methotrexateinduced Hepatoxicity Model

Overview

Journal Acta Cir Bras

Specialty General Surgery

Date 2022 Jul 27

PMID 35894304

Authors

Huseyin Acar

Omay Sorgun

Guner Yurtseve

Ejder Saylav Bora

Oytun Erbas

Affiliations

Soon will be listed here.

Abstract

Purpose: Liver damage caused by drugs and other chemicals accounts for about 5% of all cases. Methotrexate (MTX), a folic acid analogue, is a first-line synthetic antimetabolite agent routinely used in the treatment of rheumatoid arthritis and other autoimmune and chronic inflammatory diseases. Polyethylene glycol (PEG) has antioxidant activity. In this study, we evaluated biochemically and histopathologically the antifibrotic effect of PEG 3350 administered intraperitoneally to prevent methotrexate-induced liver damage in rats.

Methods: A total of 30 male rats including 10 rats was given no drugs (normal group), and 20 rats received single-dose 20 mg/kg MTXfor induced liver injury in this study. MTX was given to 20 rats, which were divided in two groups. Group 1 rats was given PEG30 mg/kg/day (Merck) intraperitoneally, and Group 2 rats % 0.9 NaCl saline 1 mL/kg/day intraperitoneally daily for two weeks.

Results: Transforming growth factor beta (TGF-β), plasma malondialdehyde (MDA), liver MDA, serum tumour necrosis factor alpha (TNF-α), alanine aminotransferase and plasma pentraxin-3 levels and, according to tissue histopathology, hepatocyte necrosis, fibrosis and cellular infiltration were significantly better in MTX+PEG group than in MTX+saline group.

Conclusions: PEG 3350 is a hope for toxic hepatitis due to other causes, since liver damage occurs through oxidative stress and cell damage, similar to all toxic drugs.

Citing Articles

Recent advances in polymeric nanoparticles for the treatment of hepatic diseases.

Gao F, Feng X, Li X Front Pharmacol. 2025; 16:1528752.

PMID: 39925843 PMC: 11802823. DOI: 10.3389/fphar.2025.1528752.

References

Jahovic N, Cevik H, Sehirli A, Yegen B, Sener G . Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res. 2003; 34(4):282-7. View

Sener G, Eksioglu-Demiralp E, Cetiner M, Ercan F, Sirvanci S, Gedik N . L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol. 2006; 22(1):47-60. DOI: 10.1007/s10565-006-0025-0. View

Abo-Haded H, Elkablawy M, Al-Johani Z, Al-Ahmadi O, El-Agamy D . Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. PLoS One. 2017; 12(3):e0174295. PMC: 5363865. DOI: 10.1371/journal.pone.0174295. View

Fabregat I, Moreno-Caceres J, Sanchez A, Dooley S, Dewidar B, Giannelli G . TGF-β signalling and liver disease. FEBS J. 2016; 283(12):2219-32. DOI: 10.1111/febs.13665. View

Lindsay K, Fraser A, Layton A, Goodfield M, Gruss H, Gough A . Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford). 2009; 48(5):569-72. DOI: 10.1093/rheumatology/kep023. View

Amaral J, Taylor P, Teixeira M, Morrison T, Schoen R . The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis. Viruses. 2019; 11(3). PMC: 6466451. DOI: 10.3390/v11030289. View

Sistanizad M, Peterson G . Drug-induced liver injury in the Australian setting. J Clin Pharm Ther. 2013; 38(2):115-20. DOI: 10.1111/jcpt.12039. View

Bejaoui M, Pantazi E, Calvo M, Folch-Puy E, Serafin A, Pasut G . Polyethylene Glycol Preconditioning: An Effective Strategy to Prevent Liver Ischemia Reperfusion Injury. Oxid Med Cell Longev. 2016; 2016:9096549. PMC: 4770158. DOI: 10.1155/2016/9096549. View

Zurad E, Johanson J . Over-the-counter laxative polyethylene glycol 3350: an evidence-based appraisal. Curr Med Res Opin. 2011; 27(7):1439-52. DOI: 10.1185/03007995.2011.580339. View

10.

Tittarelli R, Pellegrini M, Scarpellini M, Marinelli E, Bruti V, di Luca N . Hepatotoxicity of paracetamol and related fatalities. Eur Rev Med Pharmacol Sci. 2017; 21(1 Suppl):95-101. View

11.

Juarez-Moreno K, Ayala M, Vazquez-Duhalt R . Antioxidant Capacity of Poly(Ethylene Glycol) (PEG) as Protection Mechanism Against Hydrogen Peroxide Inactivation of Peroxidases. Appl Biochem Biotechnol. 2015; 177(6):1364-73. DOI: 10.1007/s12010-015-1820-y. View

12.

Cure E, Kirbas A, Tumkaya L, Cumhur Cure M, Kalkan Y, Yilmaz A . Protective effect of infliximab on methotrexate-induced liver injury in rats: unexpected drug interaction. J Cancer Res Ther. 2015; 11(1):164-9. DOI: 10.4103/0973-1482.140809. View

13.

Clemens M, McGill M, Apte U . Mechanisms and biomarkers of liver regeneration after drug-induced liver injury. Adv Pharmacol. 2019; 85:241-262. PMC: 7641498. DOI: 10.1016/bs.apha.2019.03.001. View

14.

Tsikas D . Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges. Anal Biochem. 2016; 524:13-30. DOI: 10.1016/j.ab.2016.10.021. View

15.

Narciso-Schiavon J, Pereira J, Silva T, Bansho E, Morato E, Pinheiro J . Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis. Ann Hepatol. 2017; 16(5):780-787. DOI: 10.5604/01.3001.0010.2789. View

16.

Labbe G, Pessayre D, Fromenty B . Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008; 22(4):335-53. DOI: 10.1111/j.1472-8206.2008.00608.x. View

17.

Bardallo R, Company-Marin I, Folch-Puy E, Rosello-Catafau J, Panisello-Rosello A, Carbonell T . PEG35 and Glutathione Improve Mitochondrial Function and Reduce Oxidative Stress in Cold Fatty Liver Graft Preservation. Antioxidants (Basel). 2022; 11(1). PMC: 8772919. DOI: 10.3390/antiox11010158. View

18.

Lertnawapan R, Chonprasertsuk S, Siramolpiwat S . Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate. Int J Rheum Dis. 2018; 22(2):214-221. DOI: 10.1111/1756-185X.13442. View

19.

Rahimi R, Singal A, Cuthbert J, Rockey D . Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014; 174(11):1727-33. PMC: 5609454. DOI: 10.1001/jamainternmed.2014.4746. View

20.

Verma S, Kaplowitz N . Diagnosis, management and prevention of drug-induced liver injury. Gut. 2009; 58(11):1555-64. DOI: 10.1136/gut.2008.163675. View